LIGAND PHARMACEUTICALS INC - 01 Jul 2025 SCHEDULE 13D Report for PELTHOS THERAPEUTICS INC. Common Stock, par value $0.0001 per share (CHRO)

Filing Manager: LIGAND PHARMACEUTICALS INC
Reporting Manager: Ligand Pharmaceuticals Incorporated
Security: PELTHOS THERAPEUTICS INC. Common Stock, par value $0.0001 per share
Symbol: CHRO
Shares outstanding: 9,875,487 shares
Disclosed Ownership: 4,927,868 shares
Ownership: 50%
Form type: SCHEDULE 13D
Filing time: 03 Jul 2025, 16:05:07 UTC
Date of event: 01 Jul 2025
Next filing: 10 Nov 2025
SEC: View on sec.gov

Reporting Managers (1)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Ligand Pharmaceuticals Incorporated	50%	4,927,868	4,927,868	0	/s/ Octavio Espinoza	Octavio Espinoza, Chief Financial Officer	0000886163